Search Clinical Trials
There are research studies that need you! MetroHealth conducts research studies and clinical trials to find cures and make new discoveries to improve the health and wellness of our community.
If you are interested in taking part in a MetroHealth research study, please review the list below for all active and enrolling clinical trials at MetroHealth OR narrow your search for specific conditions.
Condition of Interest |
---|
Patient-Centered Outcomes in the Surgical Treatment of Uterovaginal Prolapse
Uterine Prolapse
The purpose of this study is to compare two types of surgery for the treatment of
uterovaginal prolapse to determine which surgery works best from a patient's perspective
and has the lowest number of short-term and long-term complications. expand
The purpose of this study is to compare two types of surgery for the treatment of uterovaginal prolapse to determine which surgery works best from a patient's perspective and has the lowest number of short-term and long-term complications. Type: Interventional Start Date: Dec 2021 |
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Ch1
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
This phase II/III trial studies how well radiation therapy works when given together with
cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients
with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells
(squamous cell). Specialized radiatio1 expand
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab. Type: Interventional Start Date: Mar 2013 |
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
Coagulation Disorder
The aim of this study is to find out the effects of TAK-330 compared with four-factor
prothrombin complex concentrate (4F-PCC) as part of standard treatment other than
Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa
inhibitors who require urgent surgery/invasi1 expand
The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa inhibitors who require urgent surgery/invasive procedure. The participant will be assigned by chance to either TAK-330 or SOC 4F-PCC as part of standard treatment before surgery. Patients participating in this study will need to be hospitalized. They will also be contacted (via telehealth/phone call) 30 days after the surgery. Type: Interventional Start Date: Aug 2022 |
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smo1
Smoldering Plasma Cell Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or
without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in
chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the
growth of tumor cells, either by kill1 expand
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma. Type: Interventional Start Date: Sep 2019 |
Low Voltage-Directed Catheter Ablation for Atrial Fibrillation
Atrial Fibrillation - Symptomatic
A two-pronged approach to evaluate long term success of non-paroxysmal ablation when
using a:
1. specified low voltage-directed with pulmonary vein isolation (LD+PVI) approach
compared to ,
2. an approach of pulmonary vein isolation (PVI) alone. expand
A two-pronged approach to evaluate long term success of non-paroxysmal ablation when using a: 1. specified low voltage-directed with pulmonary vein isolation (LD+PVI) approach compared to , 2. an approach of pulmonary vein isolation (PVI) alone. Type: Interventional Start Date: Jul 2019 |
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed1
ALK Gene Rearrangement
ALK Gene Translocation
ALK Positive
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage II Non-Small Cell Lung Cancer AJCC v7
This randomized phase III trial studies how well crizotinib works in treating patients
with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a
mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in
ALK can make it very active and im1 expand
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Type: Interventional Start Date: Mar 2015 |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence1
Stage I Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy
results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor
recurrence (IBTR) compared to breast conservation with breast radiation and endocrine
therapy. expand
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy. Type: Interventional Start Date: Jun 2021 |
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Pati1
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
HER2 Negative Breast Carcinoma
Hormone Receptor Positive Breast Carcinoma
This phase III trial compares an additional support program (text message reminders
and/or telephone-based counseling) with usual care in making sure breast cancer patients
take their endocrine therapy medication as prescribed (medication adherence). Medication
adherence is how well patients take t1 expand
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed. Type: Interventional Start Date: Feb 2021 |
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High1
Prostate Adenocarcinoma
Stage III Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
This phase III trial compares stereotactic body radiation therapy (SBRT), (five
treatments over two weeks using a higher dose per treatment) to usual radiation therapy
(20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer.
SBRT uses special equipment to position a p1 expand
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment. Type: Interventional Start Date: Dec 2023 |
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
Post Operative Surgical Site Infection
The proposed study is a multi-center, prospective randomized controlled trial comparing
current standard of care treatment to the SEXTANT treatment protocol in patients with
Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot. expand
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot. Type: Interventional Start Date: May 2021 |
Reflex Excitability in Post-stroke Stiff-Knee Gait
Stroke
Chronic Stroke
Gait, Hemiplegic
Gait, Spastic
Gait Disorder, Sensorimotor
The purpose of this study is to examine the reflex excitability of the rectus femoris in
individuals with and without post-stroke Stiff-Knee gait. We use electrical stimulation
of the peripheral nerve innervating the rectus femoris for a well-controlled reflex
stimulus. We are investigating whether1 expand
The purpose of this study is to examine the reflex excitability of the rectus femoris in individuals with and without post-stroke Stiff-Knee gait. We use electrical stimulation of the peripheral nerve innervating the rectus femoris for a well-controlled reflex stimulus. We are investigating whether reflex excitability of the rectus femoris correlates with gait kinematics. Type: Interventional Start Date: Jun 2021 |
Lupus Landmark Study: A Prospective Registry and Biorepository
Systemic Lupus Erythematosus (SLE)
Lupus Nephritis
Neuropsychiatric Systemic Lupus Erythematosus
The purpose of the registry and biorepository is to provide a mechanism to store clinical
data, linked biospecimens and molecular data to support the conduct of future research on
Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN). expand
The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN). Type: Observational [Patient Registry] Start Date: Jun 2023 |
Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial
Hemorrhagic Shock
Traumatic Injury
Open label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma
centers designed to determine the efficacy and safety of low titer whole blood
resuscitation as compared to standard of care resuscitation in patients at risk of
hemorrhagic shock and to appropriately characterize t1 expand
Open label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to standard of care resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize the hemostatic competency of whole blood relative to its age. Type: Interventional Start Date: Apr 2022 |
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method
for genomic screening of similar large cancer populations followed by assigning and
accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type
of cancer trait (biomarker) will dete1 expand
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Type: Interventional Start Date: Feb 2019 |
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving
usual care that includes regional radiation therapy, with receiving no regional radiation
therapy. Researchers want to see if not giving this type of radiation treatment works as
well at preventing breast cancer1 expand
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back. Type: Interventional Start Date: Oct 2018 |
Acute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal1
Fecal Incontinence
Bowel issues occur in nearly all people after spinal cord injury (SCI) and one major
complication is fecal incontinence (accidents). This complication has been repeatedly
highlighted by people living with SCI as particularly life-limiting and in need of more
options for interventions. This study wi1 expand
Bowel issues occur in nearly all people after spinal cord injury (SCI) and one major complication is fecal incontinence (accidents). This complication has been repeatedly highlighted by people living with SCI as particularly life-limiting and in need of more options for interventions. This study will test the effect of genital nerve stimulation (GNS), with non-invasive electrodes, on the activity of the anus and rectum of persons after SCI. Recording anorectal manometry (ARM) endpoints tells us the function of those tissues and our study design (ARM without stim, ARM with stim, ARM without stim) will allow us to conclude the GNS effect and whether it is likely to reduce fecal incontinence. The study will also collect medical, demographic, and bowel related functional information. The combination of all of these data should help predict who will respond to stimulation, what will happen when stimulation is applied, and if that stimulation is likely to provide an improvement in fecal continence for people living with SCI. Type: Interventional Start Date: Mar 2023 |
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Br1
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
HER2-Positive Breast Carcinoma
Invasive Breast Carcinoma
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG)
positron emission tomography/computed tomography (PET/CT) works in predicting response to
standard of care chemotherapy prior to surgery in patients with HER2-positive stage
IIa-IIIc breast cancer. FDG is a ra1 expand
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside the body. The use of FDG-PET/CT may help doctors better decide if a patient needs more or less treatment before surgery in order to get the best response. This study evaluates whether FDG-PET/CT is useful in predicting a patient's response to standard of care chemotherapy. Type: Interventional Start Date: May 2023 |
DORAYA-HF Early Feasibility Study
Acute Decompensated Heart Failure
The study objective is to evaluate the feasibility of the Doraya Catheter and measure
clinical performance and safety endpoints, in ADHF patients deemed to have insufficient
diuretic response. expand
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response. Type: Interventional Start Date: Oct 2022 |
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-A1
Acute Kidney Injury
The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal
intervention to usual care on hospital-free days through 90 days of study follow up. The
primary study hypothesis is that patients randomized to the intervention will have
increased odds of more hospital-free d1 expand
The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rates of recurrent AKI, and changes in patient-reported outcomes. Participants (N=2145) will be allocated 1:1 to the intervention or usual care using a web-based system to maintain allocation concealment using stratified randomization with randomly permuted blocks. Randomization will be stratified by clinical site. Type: Interventional Start Date: Sep 2023 |
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Rheumatic Joint Disease
Continuation of the CARRA Registry as described in the protocol will support data
collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will
form the basis for future CARRA studies. In particular, this observational registry will
be used to answer pressing questions abo1 expand
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions. Type: Observational [Patient Registry] Start Date: Jul 2015 |
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the1
Plasma Cell Myeloma
RISS Stage I Plasma Cell Myeloma
RISS Stage II Plasma Cell Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib,
lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab,
lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell1 expand
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone. Type: Interventional Start Date: Feb 2021 |
Electrical Stimulation for Continence After Spinal Cord Injury
Spinal Cord Injury
Neurogenic Bladder
Incontinence
This study aims to improve continence and voiding of patients with spinal cord injury
using electrical stimulation.
The Finetech Vocare Bladder System is an implantable sacral nerve stimulator for
improving bladder and bowel function in patients with spinal cord injury (SCI). It has
been commercia1 expand
This study aims to improve continence and voiding of patients with spinal cord injury using electrical stimulation. The Finetech Vocare Bladder System is an implantable sacral nerve stimulator for improving bladder and bowel function in patients with spinal cord injury (SCI). It has been commercially available in Britain and other countries since 1982, and has been used in thousands of patients with SCI to improve bladder, bowel and sexual function. It received FDA approval in 1998 under Humanitarian Device Exemption H980005 and H980008 for providing urination on demand and to aid in bowel evacuation. Electrical stimulation to produce bladder contraction and improve bladder voiding after spinal cord injury has usually been combined with cutting of sensory nerves to reduce reflex contraction of the bladder, which improves continence. However, cutting these nerves has undesirable side effects. This study will not cut any sensory nerve. This study is testing the use of the stimulator for inhibiting bladder contraction by stimulating sensory nerves to improve continence after spinal cord injury, and for blocking sphincter contraction to improve voiding. Type: Interventional Start Date: Sep 2014 |
PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk C1
Chronic Obstructive Pulmonary Disease
A 3-year cluster randomized controlled trial of the impact of a quality improvement and
clinical decision support package versus usual care for patients with modifiable
high-risk chronic obstructive pulmonary disease with or without a current diagnosis. expand
A 3-year cluster randomized controlled trial of the impact of a quality improvement and clinical decision support package versus usual care for patients with modifiable high-risk chronic obstructive pulmonary disease with or without a current diagnosis. Type: Interventional Start Date: Sep 2022 |
Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: the1
HIV
AIDS
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort
that will describe clinical outcomes, and improve the quality of care for outpatients
with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) in
Washington, DC. expand
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes, and improve the quality of care for outpatients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) in Washington, DC. Type: Observational Start Date: Jan 2011 |
CPAP Adherence Pilot Study Among African Americans
Sleep Apnea
The goal of the study is to determine the feasibility of a behavioral intervention to
improve CPAP adherence among African American patients with obstructive sleep apnea. expand
The goal of the study is to determine the feasibility of a behavioral intervention to improve CPAP adherence among African American patients with obstructive sleep apnea. Type: Interventional Start Date: Feb 2023 |
- Previous
- Next